Search

Your search keyword '"Asraf, Keren"' showing total 28 results
Start Over Author "Asraf, Keren" Search Limiters Full Text
28 results on '"Asraf, Keren"'

1. SARS-CoV-2 IgG Levels as Predictors of XBB Variant Neutralization, Israel, 2022 and 2023

Author

Lustig, Yaniv, Canetti, Michal, Indenbaum, Victoria, Peretz, Yovel, Weiss- Ottolenghi, Yael, Margalit, Ili, Asraf, Keren, Levin, Tal, Zuckerman, Neta, Tomer, Enosh, Mandelboim, Michal, Doolman, Ram, Barda, Noam, and Regev-Yochay, Gili

Subjects
Immunological research, Immune response -- Research, Immunoglobulin G -- Measurement -- Physiological aspects, Health
Abstract

Since the beginning of 2023, SARS-CoV-2 Omicron XBB variants have led as the cause of global SARS-CoV-2 infections (1,2). SARS-CoV-2 mRNA vaccines based on the ancestral variant were shown to [...]

Published
2024
Full Text
View/download PDF

3. Immunogenicity of Omicron BA.1-adapted BNT162b2 vaccines: randomized trial, 3-month follow-up

Author

Barda, Noam, Lustig, Yaniv, Indenbaum, Victoria, Zibly, Daniel, Joseph, Gili, Asraf, Keren, Weiss-Ottolenghi, Yael, Amit, Sharon, Kliker, Limor, Abd Elkader, Bayan, Ben-Ami, Eytan, Canetti, Michal, Koren, Ravit, Katz-Likvornik, Shiri, Halpern, Osnat, Mendelson, Ella, Doolman, Ram, Harats, Dror, Kreiss, Yitshak, Mandelboim, Michal, and Regev-Yochay, Gili

Published
2023
Full Text
View/download PDF

5. Corrigendum to 'Immunogenicity of Omicron BA.1-adapted BNT162b2 vaccines: randomized trial, 3-month follow-up', Clinical Microbiology and Infection Volume 29, Issue 7, July 2023, Pages 918-923

Author

Barda, Noam, primary, Lustig, Yaniv, additional, Indenbaum, Victoria, additional, Zibly, Daniel, additional, Joseph, Gili, additional, Asraf, Keren, additional, Weiss-Ottolenghi, Yael, additional, Amit, Sharon, additional, Kliker, Limor, additional, Abu-Kadar, Bian, additional, Ben-Ami, Eytan, additional, Canetti, Michal, additional, Koren, Ravit, additional, Katz-Likvornik, Shiri, additional, Halpern, Osnat, additional, Mendelson, Ella, additional, Doolman, Ram, additional, Harats, Dror, additional, Kreiss, Yitshak, additional, Mandelboim, Michal, additional, and Regev-Yochay, Gili, additional

Published
2023
Full Text
View/download PDF

8. Corrigendum to “Immunogenicity of Omicron BA.1-adapted BNT162b2 vaccines: randomized trial, 3-month follow-up” [Clin Microbiol Infect] 29 (7) (2023) 918–923

Author

Barda, Noam, Lustig, Yaniv, Indenbaum, Victoria, Zibly, Daniel, Joseph, Gili, Asraf, Keren, Weiss-Ottolenghi, Yael, Amit, Sharon, Kliker, Limor, Abu-Kadar, Bian, Ben-Ami, Eytan, Canetti, Michal, Koren, Ravit, Katz-Likvornik, Shiri, Halpern, Osnat, Mendelson, Ella, Doolman, Ram, Harats, Dror, Kreiss, Yitshak, Mandelboim, Michal, and Regev-Yochay, Gili

Published
2024
Full Text
View/download PDF

9. Humoral Immunity of Unvaccinated COVID-19 Recovered vs. Naïve BNT162b2 Vaccinated Individuals: A Prospective Longitudinal Study

Author

Joseph, Gili, primary, Cohen, Carmit, additional, Rubin, Carmit, additional, Murad, Havi, additional, Indenbaum, Victoria, additional, Asraf, Keren, additional, Weiss-Ottolenghi, Yael, additional, Segal-Lieberman, Gabriella, additional, Kreiss, Yitshak, additional, Lustig, Yaniv, additional, and Regev-Yochay, Gili, additional

Published
2023
Full Text
View/download PDF

10. Factors Associated With Protection From SARS-CoV-2 Omicron Variant Infection and Disease Among Vaccinated Health Care Workers in Israel

Author

Gilboa, Mayan, primary, Gonen, Tal, additional, Barda, Noam, additional, Cohn, Shelly, additional, Indenbaum, Victoria, additional, Weiss-Ottolenghi, Yael, additional, Amit, Sharon, additional, Asraf, Keren, additional, Joseph, Gili, additional, Levin, Tal, additional, Kanaaneh, Yara, additional, Aydenzon, Alex, additional, Canetti, Michal, additional, Freedman, Laurence, additional, Zuckerman, Neta, additional, Mendelson, Ella, additional, Doolman, Ram, additional, Kreiss, Yitshak, additional, Regev-Yochay, Gili, additional, and Lustig, Yaniv, additional

Published
2023
Full Text
View/download PDF

11. Correlates of protection against COVID-19 infection and intensity of symptomatic disease in vaccinated individuals exposed to SARS-CoV-2 in households in Israel (ICoFS): a prospective cohort study

Author

Regev-Yochay, Gili, primary, Lustig, Yaniv, additional, Joseph, Gili, additional, Gilboa, Mayan, additional, Barda, Noam, additional, Gens, Ilana, additional, Indenbaum, Victoria, additional, Halpern, Osnat, additional, Katz-Likvornik, Shiri, additional, Levin, Tal, additional, Kanaaneh, Yara, additional, Asraf, Keren, additional, Amit, Sharon, additional, Rubin, Carmit, additional, Ziv, Arnona, additional, Koren, Ravit, additional, Mandelboim, Michal, additional, Tokayer, Noam H, additional, Meltzer, Lilac, additional, Doolman, Ram, additional, Mendelson, Ella, additional, Alroy-Preis, Sharon, additional, and Kreiss, Yitshak, additional

Published
2023
Full Text
View/download PDF

12. Reduced Neutralization Efficacy against Omicron Variant after Third Boost of BNT162b2 Vaccine among Liver Transplant Recipients

Author

Davidov, Yana, primary, Indenbaum, Victoria, additional, Mandelboim, Michal, additional, Asraf, Keren, additional, Gonen, Tal, additional, Tsaraf, Keren, additional, Cohen-Ezra, Oranit, additional, Likhter, Mariya, additional, Nemet, Ital, additional, Kliker, Limor, additional, Mor, Orna, additional, Doolman, Ram, additional, Cohen, Carmit, additional, Afek, Arnon, additional, Kreiss, Yitshak, additional, Regev-Yochay, Gili, additional, Lustig, Yaniv, additional, and Ben-Ari, Ziv, additional

Published
2023
Full Text
View/download PDF

13. High Immune Response Rate to the Fourth Boost of the BNT162b2 Vaccine against the Omicron Variants of Concern among Liver Transplant Recipients

Author

Davidov, Yana, primary, Indenbaum, Victoria, additional, Atari, Nofar, additional, Kliker, Limor, additional, Tsaraf, Keren, additional, Asraf, Keren, additional, Cohen-Ezra, Oranit, additional, Likhter, Mariya, additional, Mor, Orna, additional, Doolman, Ram, additional, Weiss-Ottolenghi, Yael, additional, Hod, Tammy, additional, Afek, Arnon, additional, Kreiss, Yitshak, additional, Lustig, Yaniv, additional, Regev-Yochay, Gili, additional, Mandelboim, Michal, additional, and Ben-Ari, Ziv, additional

Published
2022
Full Text
View/download PDF

15. Real-World Immunogenicity and Reactogenicity of Two Doses of Pfizer-BioNTech COVID-19 Vaccination in Children Aged 5–11 Years

Author

Joseph, Gili, primary, Klein, Elisheva, additional, Lustig, Yaniv, additional, Weiss-Ottolenghi, Yael, additional, Asraf, Keren, additional, Indenbaum, Victoria, additional, Amit, Sharon, additional, Kriger, Or, additional, Gilboa, Mayan, additional, Levy, Yuval, additional, Pessach, Itai M., additional, Kreiss, Yitshak, additional, Regev-Yochay, Gili, additional, and Stein, Michal, additional

Published
2022
Full Text
View/download PDF

16. Comparing immunogenicity and efficacy of two different mRNA-based COVID-19 vaccines as a fourth dose; six-month follow-up, Israel, 27 December 2021 to 24 July 2022

Author

Barda, Noam, primary, Canetti, Michal, additional, Gilboa, Mayan, additional, Indenboim, Victoria, additional, Asraf, Keren, additional, Weiss-Ottolenghi, Yael, additional, Amit, Sharon, additional, Zibly, Daniel, additional, Doolman, Ram, additional, Mendelson, Ella, additional, Harats, Dror, additional, Freedman, Laurence S., additional, Kreiss, Yitshak, additional, Lustig, Yaniv, additional, and Regev-Yochay, Gili, additional

Published
2022
Full Text
View/download PDF

17. Durability of Immune Response After COVID-19 Booster Vaccination and Association With COVID-19 Omicron Infection

Author

Gilboa, Mayan, primary, Regev-Yochay, Gili, additional, Mandelboim, Michal, additional, Indenbaum, Victoria, additional, Asraf, Keren, additional, Fluss, Ronen, additional, Amit, Sharon, additional, Mendelson, Ella, additional, Doolman, Ram, additional, Afek, Arnon, additional, Freedman, Laurence S., additional, Kreiss, Yitshak, additional, and Lustig, Yaniv, additional

Published
2022
Full Text
View/download PDF

20. Correlation between Adverse Events and Antibody Titers among Healthcare Workers Vaccinated with BNT162b2 mRNA COVID-19 Vaccine

Author

Levy, Itzchak, primary, Levin, Einav Gal, additional, Olmer, Liraz, additional, Regev-Yochay, Gili, additional, Agmon-Levin, Nancy, additional, Wieder-Finesod, Anat, additional, Indenbaum, Victoria, additional, Herzog, Karin, additional, Doolman, Ram, additional, Asraf, Keren, additional, Halperin, Rebecca, additional, Lustig, Yaniv, additional, and Rahav, Galia, additional

Published
2022
Full Text
View/download PDF

21. The Predictive Value of Serum ACE2 and TMPRSS2 Concentrations in Patients with COVID-19—A Prospective Pilot Study

Author

Kassif Lerner, Reut, primary, Stein Yeshurun, Michal, additional, Hemi, Rina, additional, Zada, Nahid, additional, Asraf, Keren, additional, Doolman, Ram, additional, Benoit, Stefanie W., additional, Santos de Oliveira, Maria Helena, additional, Lippi, Giuseppe, additional, Henry, Brandon Michael, additional, Pessach, Itai M., additional, and Pode Shakked, Naomi, additional

Published
2022
Full Text
View/download PDF

23. Potential antigenic cross-reactivity between SARS-CoV-2 and Dengue viruses

Author

Lustig, Yaniv, Keler, Shlomit, Kolodny, Rachel, Ben-Tal, Nir, Atias-Varon, Danit, Shlush, Ekaterina, Gerlic, Motti, Munitz, Ariel, Doolman, Ram, Asraf, Keren, Shlush, Liran I, and Vivante, Asaf

Subjects
Dengue, AcademicSubjects/MED00290, SARS-CoV-2, Major Article, COVID-19, Humans, Cross Reactions, Dengue Virus, Antibodies, Viral, West Nile
Abstract

Coronavirus disease 2019 (COVID-19) and dengue fever are difficult to distinguish given shared clinical and laboratory features. Failing to consider COVID-19 due to false-positive dengue serology can have serious implications. We aimed to assess this possible cross-reactivity.We analyzed clinical data and serum samples from 55 individuals with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. To assess dengue serology status, we used dengue-specific antibodies by means of lateral-flow rapid test, as well as enzyme-linked immunosorbent assay (ELISA). Additionally, we tested SARS-CoV-2 serology status in patients with dengue and performed in-silico protein structural analysis to identify epitope similarities.Using the dengue lateral-flow rapid test we detected 12 positive cases out of the 55 (21.8%) COVID-19 patients versus zero positive cases in a control group of 70 healthy individuals (P = 2.5E-5). This includes 9 cases of positive immunoglobulin M (IgM), 2 cases of positive immunoglobulin G (IgG), and 1 case of positive IgM as well as IgG antibodies. ELISA testing for dengue was positive in 2 additional subjects using envelope protein directed antibodies. Out of 95 samples obtained from patients diagnosed with dengue before September 2019, SARS-CoV-2 serology targeting the S protein was positive/equivocal in 21 (22%) (16 IgA, 5 IgG) versus 4 positives/equivocal in 102 controls (4%) (P = 1.6E-4). Subsequent in-silico analysis revealed possible similarities between SARS-CoV-2 epitopes in the HR2 domain of the spike protein and the dengue envelope protein.Our findings support possible cross-reactivity between dengue virus and SARS-CoV-2, which can lead to false-positive dengue serology among COVID-19 patients and vice versa. This can have serious consequences for both patient care and public health.

Published
2020

27. Involvement of the Bradykinin B1 Receptor in Microglial Activation: In Vitro and In Vivo Studies.

Author

Asraf, Keren, Torika, Nofar, Danon, Abraham, and Fleisher-Berkovich, Sigal

Subjects
BRADYKININ receptors, MICROGLIA, ALZHEIMER'S disease treatment, PHYSIOLOGY
Abstract

The importance of brain inflammation to Alzheimer's disease (AD) pathogenesis has been accepted of late, with it currently being held that brain inflammation aggravates AD pathology. One important aspect of brain inflammation is the recruitment and activation of microglia, a process termed microgliosis. Kinins and bradykinin (BK), in particular, are major pro-inflammatory mediators in the periphery, although all of the factors comprising the kinin system have also been described in the brain. Moreover, it was shown that the amyloid β (Aβ) peptide (a component of AD plaques) enhances kinin secretion and activates BK receptors that can, in turn, stimulate Aβ production. Still, the role of bradykinin in modulating brain inflammation and AD is not completely understood. In this study, we aimed to investigate the roles of the bradykinin B1 receptor (B1R) and bradykinin B2 receptor (B2R) in regulating microglial secretion of pro-inflammatory factors in vitro. Furthermore, the effects of intranasal administration of specific B1R and B2R antagonists on Aβ burden and microglial accumulation in the brains of transgenic AD mice were studied. The data obtained show that neither R-715 (a B1R antagonist) nor HOE 140 (a B2R antagonist) altered microglial cell viability. However, R-715, but not HOE 140, markedly increased lipopolysaccharide-induced nitric oxide (NO) and tumor necrosis factor-alpha (TNF-α) release, as well as inducible nitric oxide synthase expression in BV2 microglial cells. Neither antagonist altered NO nor TNF-α production in nonstimulated cells. We also showed that intranasal administration of R-715 but not HOE 140 to 8-week-old 5X familial AD mice enhanced amyloid burden and microglia/macrophage accumulation in the cortex. To conclude, we provide evidence supporting a role of B1R in brain inflammation and in the regulation of amyloid deposition in AD mice, possibly with microglial/macrophage involvement. Further studies are required to test whether modulation of this receptor can serve as a novel therapeutic strategy for AD. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

28. Involvement of the Bradykinin B 1 Receptor in Microglial Activation: In Vitro and In Vivo Studies.

Author

Asraf K, Torika N, Danon A, and Fleisher-Berkovich S

Abstract

The importance of brain inflammation to Alzheimer's disease (AD) pathogenesis has been accepted of late, with it currently being held that brain inflammation aggravates AD pathology. One important aspect of brain inflammation is the recruitment and activation of microglia, a process termed microgliosis. Kinins and bradykinin (BK), in particular, are major pro-inflammatory mediators in the periphery, although all of the factors comprising the kinin system have also been described in the brain. Moreover, it was shown that the amyloid β (Aβ) peptide (a component of AD plaques) enhances kinin secretion and activates BK receptors that can, in turn, stimulate Aβ production. Still, the role of bradykinin in modulating brain inflammation and AD is not completely understood. In this study, we aimed to investigate the roles of the bradykinin B 1 receptor (B 1 R) and bradykinin B 2 receptor (B 2 R) in regulating microglial secretion of pro-inflammatory factors in vitro . Furthermore, the effects of intranasal administration of specific B 1 R and B 2 R antagonists on Aβ burden and microglial accumulation in the brains of transgenic AD mice were studied. The data obtained show that neither R-715 (a B 1 R antagonist) nor HOE 140 (a B 2 R antagonist) altered microglial cell viability. However, R-715, but not HOE 140, markedly increased lipopolysaccharide-induced nitric oxide (NO) and tumor necrosis factor-alpha (TNF-α) release, as well as inducible nitric oxide synthase expression in BV2 microglial cells. Neither antagonist altered NO nor TNF-α production in non-stimulated cells. We also showed that intranasal administration of R-715 but not HOE 140 to 8-week-old 5X familial AD mice enhanced amyloid burden and microglia/macrophage accumulation in the cortex. To conclude, we provide evidence supporting a role of B 1 R in brain inflammation and in the regulation of amyloid deposition in AD mice, possibly with microglial/macrophage involvement. Further studies are required to test whether modulation of this receptor can serve as a novel therapeutic strategy for AD.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results